NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma
Recruiting
Phase 1
Interventional Study
Non Hodgkin Lymphoma (NHL)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 19 – 80
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 9 (estimated)
- Sponsor
- NOBO Medicine · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients with relapsed/refractory NHL including FL, MCL and MZL
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age 19 to 80 years.
2. Patients must voluntarily agree to participate in the study and provide written informed consent prior to any study-related procedures.
3. Patients with histologically confirmed follicular lymphoma, mantle cell lymphoma or marginal zone lymphoma.
4. rel…
Contacts
No contact information available.